Brief: Cadrenal Therapeutics Granted FDA Fast Track Designation For Tecarfarin For Prevention Of Systemic Thromboembolism Of Cardiac Origin In Patients With End-Stage Renal Disease And Atrial Fibrillation
23/01/2023 13:44
Jan 23 (Reuters) - Cadrenal Therapeutics Inc CVKD.O :
* CADRENAL THERAPEUTICS (NASDAQ: CVKD) GRANTED FDA FAST
TRACK
DESIGNATION FOR TECARFARIN FOR PREVENTION OF SYSTEMIC
THROMBOEMBOLISM OF CARDIAC ORIGIN IN PATIENTS WITH END-STAGE
RENAL DISEASE AND ATRIAL FIBRILLATION
Source text for Eikon: ID:nPn35Wwgha
Further company coverage: CVKD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cadrenal Therapeutics
See all newsCadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology